Alnylam Pharmaceuticals

The U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling in favor of Moderna, rejecting Alnylam Pharmaceuticals' patent infringement claims over mRNA-based COVID-19 vaccine technology.

DelveInsight's 2025 pipeline analysis reveals over 20 active companies developing more than 20 pipeline drugs for Huntington's disease, including gene-targeting and disease-modifying therapies.

Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics.

Comprehensive analysis of 700+ pharmaceutical and biotechnology partnering deals with disclosed royalty rates from 2010-2025 has been published by ResearchAndMarkets.com.

Novartis's LEQVIO (inclisiran), the first FDA-approved siRNA therapy for LDL-C reduction, is projected to reach USD 2.2 billion in US market size by 2034, offering a novel mechanism with biannual dosing that enhances patient adherence.

Alnylam Pharmaceuticals has requested a Delaware federal court to end its patent infringement case against Pfizer and BioNTech following an unfavorable patent interpretation ruling.

Vir Biotechnology will present 24-week subgroup analysis data from its Phase 2 SOLSTICE trial in chronic hepatitis delta at the EASL Congress 2025 in Amsterdam, examining how baseline viral parameters and cirrhosis status affect treatment responses.

DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ therapies for IgA nephropathy treatment, representing a robust therapeutic landscape.

The FDA has approved Alnylam Pharmaceuticals' AMVUTTRA (vutrisiran) for treating cardiomyopathy in adults with wild-type or hereditary transthyretin-mediated amyloidosis, designed to reduce cardiovascular mortality and hospitalizations.

Alnylam Pharmaceuticals has received FDA approval for Amvuttra (vutrisiran) to treat ATTR cardiomyopathy (ATTR-CM), significantly expanding the drug's addressable patient population beyond its original polyneuropathy indication.